Helicobacter Pylori (H. pylori) Non-Invasive Testing Market Hit USD USD 800.04 million by 2028 | Exhibit a CAGR of 4.4%

The Helicobacter Pylori (H. pylori) non-invasive testing market is expected to grow from US$ 596.82 million in 2021 to US$ 800.04 million by 2028; it is estimated to grow at a CAGR of 4.4% from 2022 to 2028.

DiaSorin S.p.A.; Meridian Bioscience, Inc.; Exalenz Bioscience Ltd.; Alere; Thermo Fisher Scientific; Biomerica, Inc.; Abbott; and CerTest Biotec are among the leading companies operating in the global Helicobacter Pylori (H. pylori) non-invasive testing market.

Request for sample PDF Copy @ https://www.theinsightpartners.com/sample/TIPRE00005185/?utm_source=OpenPR&utm_medium=10144

The COVID-19 pandemic substantially influenced the global Helicobacter Pylori (H. pylori) non-invasive testing market. This is mainly due to the presence of H. pylori in COVID-19 patients causing abdominal pain and diarrhea. SARS-CoV-2 enters cells through binding angiotensin-converting enzymes (ACE-2) receptors, and H. pylori are responsible for increasing the expression of ACE-2 receptors in the gastrointestinal tract. Therefore, with substantial relation between H. pylori and COVID-19, there has been considerable demand for H. pylori non-invasive testing, positively impacting the market revenue growth during the forecast period.

In 2021, the urea breath segment held the largest share of the market. In addition, owing to growing availability, the urea breath is expected to register the highest CAGR and will hold a major market share during the forecast period. Based on test method, the Helicobacter Pylori (H. pylori ) Noninvasive Testing Market is bifurcated into laboratory based and point-of-care. The laboratory based segment held a larger market share in 2021 and is likely to continue its dominance during the forecast period. Based on end user, the Helicobacter Pylori (H. pylori ) Noninvasive Testing Market is segmented into clinics, hospitals, diagnostic laboratories, and hospitals.

The global Helicobacter Pylori (H. pylori) non-invasive testing market is expected to grow significantly during the forecast period. The growth is mainly attributed to the global increase in the prevalence of H. pylori infection and the rapid use of non-invasive tests. Patients and healthcare providers have an increased preference for non-invasive tests due to their quick turnaround time for test results, increased patient compliance, and diminished discomfort.

In 2021, Biomerica signed a five-year distribution agreement with a Canadian partner to distribute and market Biomerica's new and proprietary H. pylori test, called hp+detect. The product has been developed to identify and monitor H. pylori infection. Biomerica's distribution partner will now seek Health Canada clearance using the clinical data generated by Biomerica using hp+detect to sell the product in Canada.

In 2020, Meridian Bioscience entered a definitive agreement to acquire Exalenz for ~US$ 49 million. Under the terms of the agreement, Meridian will be adding Exalenz's flagship BreathID® Breath Test Systems, a urea breath platform for the detection of H. pylori.

Place a Purchase Order to Buy a Complete Copy of this Report @ https://www.theinsightpartners.com/buy/TIPRE00005185/?utm_source=OpenPR&utm_medium=10144

About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-9876

This release was published on openPR.